New Medicare rules may help little-known Affymax (AFFY +0.2%) grab market share from Amgen's...

|By:, SA News Editor

New Medicare rules may help little-known Affymax (AFFY +0.2%) grab market share from Amgen's (AMGN -0.2%) $2.6B anemia drug Epogen with a treatment set to be approved next year.